NIPH Clinical Trials Search

NDB Analysis of ILD and OSE for Datroway

Basic Information

Recruitment status	Not Recruiting
Health condition(s) or Problem(s) studied	Breast Cancer
Date of first enrollment	15/04/2027
Target sample size	1500
Countries of recruitment
Study type	Observational
Intervention(s)

Outcome(s)

Primary Outcome	Interstitial lung disease (ILD) event Ocular surface events (OSE) related event
Secondary Outcome	Proper management of ILD and OSE Treatment for OSE

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	1) Patients with a prescription of the study drug during the inclusion period (March 19, 2025 to March 31, 2026). 2) Patients with presence of a breast cancer diagnosis (includes suspected diagnoses) in the same month as the cohort entry date.
Exclude criteria	1) Patients who have prescriptions of any anticancer drug other than the study drug on the cohort entry date.